Armata Pharmaceuticals, Inc. — Capital/Financing Update 2007

Jan 11, 2007

8-K 1 v062377_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 11, 2007

Targeted Genetics Corporation

(Exact name of registrant as specified in its charter)

Washington	0-23930	91-1549568
(State
or other jurisdiction of
incorporation)	(Commission
File Number)	(IRS
Employer Identification
No.)

| 1100
Olive Way, Suite 100, Seattle, Washington | 98101 |
| --- | --- |
| (Address
of principal executive offices) | (Zip
Code) |

Registrant’s telephone number, including area code (206) 623-7612

Not Applicable

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
| --- | --- |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |

Item 8.01 Other Events.

On January 11, 2007, Targeted Genetics announced the closing of an $8.72 million private placement of common stock and warrants to institutional and other accredited purchasers, with net proceeds to Targeted Genetics of approximately $8.1 million. Pacific Growth Equities, LLC acted as the exclusive placement agent for the financing. The terms of the private placement were described in Targeted Genetics Current Report on Form 8-K filed on January 8, 2007.

A copy of the press release issued in connection with this announcement is filed with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The Current Report on Form 8-K filed by Targeted Genetics on January 8, 2007 is also incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

99.1 Press Release of Targeted Genetics Corporation dated January 11, 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| TARGETED
GENETICS CORPORATION | |
| --- | --- |
| By: | /s/
David J. Poston |
| | David
J. Poston |
| | Vice
President Finance and Chief Financial Officer |

Dated: January 11, 2007

INDEX TO EXHIBITS

99.1 Press Release of Targeted Genetics Corporation dated January 11, 2007